CYAPO913
Diabetes
DiscoveryActive
Key Facts
About FibroBiologics
FibroBiologics is developing a novel class of biologic treatments based on fibroblasts, one of the most abundant cells in the human body. The company claims its fibroblast platform offers superior potency, easier sourcing, and lower manufacturing costs compared to stem cell therapies. With over 270 patents and an IND-cleared program for degenerative disc disease, FibroBiologics is positioning itself as a leader in next-generation regenerative medicine.
View full company profileTherapeutic Areas
Other Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Toujeo | Sanofi | Commercial |
| Lantus | Sanofi | Commercial |
| Semglee (insulin glargine biosimilar) | Viatris | Approved |
| Semglee (Insulin Glargine) | Biocon | Approved |
| Insulin Aspart | Biocon | Phase 3 |
| Liraglutide | Biocon | Phase 3 |
| MK-1293 (insulin glargine biosimilar) | Organon | Approved/Filed |
| Insulin Glargine (Biosimilar) | Gulf Pharmaceutical Industries | Approved/Commercial |